uniQure (NASDAQ:QURE) Shares Acquired by Franklin Resources Inc.

Franklin Resources Inc. raised its position in shares of uniQure (NASDAQ:QURE) by 33.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,987,688 shares of the biotechnology company’s stock after purchasing an additional 494,726 shares during the quarter. Franklin Resources Inc.’s holdings in uniQure were worth $35,103,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Twin Tree Management LP acquired a new stake in shares of uniQure during the 4th quarter valued at approximately $77,000. FNY Investment Advisers LLC bought a new stake in uniQure during the fourth quarter valued at $88,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares during the period. Quarry LP acquired a new stake in shares of uniQure during the third quarter worth $58,000. Finally, Oppenheimer & Co. Inc. bought a new position in shares of uniQure in the 4th quarter worth about $320,000. Institutional investors own 78.83% of the company’s stock.

uniQure Trading Down 8.1 %

Shares of QURE stock opened at $8.96 on Friday. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The firm has a market capitalization of $484.53 million, a PE ratio of -1.81 and a beta of 0.37. The stock has a fifty day moving average of $13.25 and a two-hundred day moving average of $10.94. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

Wall Street Analyst Weigh In

QURE has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of uniQure in a research report on Tuesday, March 4th. Wells Fargo & Company lowered their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Mizuho upped their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. Finally, The Goldman Sachs Group increased their target price on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.80.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the transaction, the chief financial officer now owns 155,168 shares in the company, valued at $1,756,501.76. This represents a 1.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock worth $961,401 over the last ninety days. 4.74% of the stock is currently owned by corporate insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.